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Background: Monitoring and improving quality of cancer care has become pivotal
today. This is especially relevant for head and neck cancers since the disease is complex,
it needs multi therapy, patients tend to be older, they tend to have comorbidities and
limited social support. However, information on quality of care for head and neck cancers
is scarce. In the context of the project “Information Network on Rare Cancers” we
aimed to identify indicators of quality of care specific for the head and neck cancers
management and to measure the quality of care for head and neck cancers in different
EU Member States.
Methods: We defined indicators of quality of care for head and neck cancers based
on a multidisciplinary and expert-based consensus process at a European level. To test
the proposed indicators, we performed an observational population-based retrospective
study in four countries (Ireland, Italy, Netherlands, and Slovenia) in the years 2009–2011.
Results: The main quality indicators identified are: availability of formalized
multidisciplinary team, participation in clinical and translational research; timeliness
of care, high quality of surgery and radiotherapy, and of pathological reporting. For head
and neck cancers, the quality of care did not reach the optimal standards in most of
the countries analyzed. A high proportion of patients was diagnosed at an advanced
disease stage, showed delays in starting treatment (especially for radiotherapy), and
there was only a very limited use of multi therapy.
Conclusions: According to the achieved consensus, indicators of quality of care for
head and neck cancers have to cover the patient journey (i.e., diagnosis and treatment).
Our results, showed suboptimal quality of care across countries and call for solutions for
ensuring good quality of care for head and neck cancer patients in all EU countries. One
possible option might be to refer head and neck cancer patients to specialized centers
or to networks including specialized centers.
Keywords: head and neck cancers, population based studies, quality of care, quality indicators, integrated care
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INTRODUCTION
Due to the complexity of oncological care, it is essential to
deliver integrated care with optimal alignment and collaboration
of several disciplines (1). This is especially relevant for
head and neck cancers (HNCs). HNCs involve different
anatomical sites, including larynx, oral cavity, oropharynx,
hypopharynx, nasopharynx, nasal cavity, and sinuses. The disease
is complex, often needs multi therapy, including surgery,
radiation, chemotherapy, and/or targeted therapy. Patients tend
to be older, to have comorbidities and less social support (2).
In order to improve high-quality oncological care, reliable
quality indicators (QIs) are indispensable. This was first
highlighted in the USA by the Institute of Medicine’s report,
“Crossing the Quality Chasm: A New Health System for the
twenty-first Century” (3). In Europe, reviews on QI of cancer
care were made available by the European Partnership for Action
Against Cancer (http://www.epaac.eu) and by the European
CanCer Organisation Essential Requirements for Quality Cancer
Care (ERQCC) (https://www.ecco-org.eu/Global/News/Latest-
News/2017/02/ECCO-Essential-Requirements-for-Quality-
Cancer-Care). With regards to HNCs, quality assurance (QA)
has been extensively addressed for HNC radiotherapy (RT) (4, 5)
and surgery (6, 7) and to a lesser extent for medical oncology
(1, 8–11).
Against this background, in the framework of the Information
network on rare cancers (RARECAREnet) project (www.
rarecarenet.eu), we defined QIs to measure quality of oncological
care for the HNC patient journey (i.e., diagnosis and treatment).
In this paper, we report on: (1) the QIs of cancer care for HNC
identified by RARECAREnet; (2) the results of the study testing
the proposed QIs in several EU countries.
MATERIALS AND METHODS
Quality indicators for HNC were defined through a consensus
process following the steps below:
1. Identification of published QIs;
2. Discussion of the proposed QIs with an expert panel involving
multidisciplinary experts in a dedicated meeting;
3. Population-based observational study in several European
countries to test the proposed QIs;
4. Discussions about the results of the observational assessment
with the same expert panel in a second meeting in which a
final agreement on QIs was achieved with no dissent. During
this second meeting, the expert panel confirmed the QIs
originally proposed and added new indicators. For the latter,
data were not collected because the observational assessment
had ended. We refer to them as QIs agreed by consensus only
(Table 1).
The HNC multidisciplinary expert panel included faculty
members of the European Society for Medical Oncology
(ESMO), authors of the ESMO clinical practice guidelines
(CPG), representatives of the European Head and Neck Society
(EHNS), of the European Society for Radiotherapy and Oncology
(ESTRO) and representatives of the European Society of Surgical
Oncology (ESSO). HNC patients were represented by the
Italian association of laryngectomized patients (Associazione
Italiana Laringectomizzati), which is a member of the Make
Sense Campaign of the EHNS, and by the European Cancer
Patient Coalition.
The observational assessment was performed in collaboration
with population-based cancer registries (CRs): the national CRs
of Ireland, Netherlands, and Slovenia, as well as nine Italian
regional CRs. The study included only incident squamous
cell carcinoma (SCC) of larynx, oral cavity, oropharynx, and
hypopharynx, diagnosed in patients>15 years old. In Ireland and
Netherlands all incident SCC of larynx, oral cavity, oropharynx,
and hypopharynx were included in the study. In Slovenia, the
study focused only on larynx however, all incident cases of larynx
SCC diagnosed in Slovenia were included. In Italy, due to the
lack of a national CR, nine CRs representative of the different
incidence rates of HNCs considered were included. These nine
CRs included all incident cases of larynx, oral cavity, oropharynx,
and hypopharynx SCC diagnosed in the geographical areas
covered by the selected nine CRs. Table 2 enlists the number of
cases included by country and the years of diagnosis.
We developed a data collection protocol with HNC clinical
experts and CRs, we established a help desk to answer questions
on the data collection and we centralized at the Istituto Nazionale
Tumori (INT) data quality checks and analyses. All data obtained
from CRs were fully anonymized prior to being accessed
centrally at INT. The Ethics Committee of INT was notified
about the RARECAREnet project including this retrospective
observational study.
For HNCs, clinical stage was adapted from the ESMO CPG
(13) breaking down patient populations into:
- Localized: T1-T2, N0, M0
- Advanced: T3-T4, N0, M0, or N+ with any T
- Metastatic: M+
- Unknown.
The treatment combinations for HNCs were defined as follows:
- Surgery alone; RT alone; chemotherapy alone (if each started
within 3 months from diagnosis),
- Concomitant chemo-radiotherapy (CRT) (if chemotherapy
and radiotherapy started on the same day, or if chemotherapy
started 1 day before the radiotherapy or within max 21 days
after the start of radiotherapy),
- Surgery + radiotherapy or surgery + concomitant
radio-chemotherapy (concomitant if chemotherapy and
radiotherapy started on the same day, or chemotherapy
started 1 day before the radiotherapy or within max 21 days
after the start of radiotherapy),
- Other combinations of treatments,
- No treatment.
RESULTS
Table 1 summarizes the RARECAREnet quality of care indicators
for HNCs. All QIs are listed i.e., QI agreed by consensus
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TABLE 1 | List of quality indicators for head and neck cancers.
Diagnostic management
1. Percentage of patients with a defined stage at diagnosis
Time to start treatment (12) and treatment adherence to clinical guidelines (13)
2. Time to start treatment (time between definitive pathological diagnosis and beginning of surgery or radiotherapy <1 month)
3. Time in starting post-operative radiotherapy or concomitant chemo-radiotherapy (<8 weeks from surgery)
4. Percentage of patients with early stage I and II referred for either surgery or radiotherapy
5. Percentage of patients with locally advanced stage III and IV referred for surgery plus post-operative radiotherapy or post-operative chemo-radiotherapy or
concomitant chemo-radiotherapy
Quality of surgery and radiotherapy
6. Percentage of complete tumor resection (histological verification of tumor free margins after surgery)
7. Percentage of re-operation within 30 days from main surgery*
8. Percentage of grade ≥3 late toxicities (>3 months after radiotherapy)*
9. Percentage of patients receiving intensity-modulated radiation therapy vs. % receiving 3D conformal radiation therapy
10. Percentage of patients receiving the appropriate surgery for its stage (e.g., minimal invasive, reconstructive surgery)*
Quality of pathology reports after surgery
11. Percentage of pathology reports after surgery with a full set of core data items recorded. According to the Royal College of Pathologists (https://www.rcpath.org/
profession/publications/cancer-datasets.html): site and laterality of the carcinoma, maximum diameter of tumor, maximum depth of invasion, histological type of
carcinoma, degree of differentiation (grade), pattern of invasion, margin status, lymph node involvement.
Availability of formalized multidisciplinary decision (with member experts on head and neck cancers)*
Participation in clinical and translational research*
*Indicators agreed by consensus within the expert panel only.
TABLE 2 | Number of patients with head and neck cancers (HNCs) included in
the study by country with years of diagnosis.
Cancer Number
Total Ireland Italy* Netherlands Slovenia
HNCs 8,655 1,323 928 6,185 219
Hypopharynx 790 121 54 615 0
Larynx 3,168 449 398 2,102 219
Oral cavity 2,976 428 258 2,290 0
Oropharynx 1,722 325 218 1,178 0
Years of diagnosis 2009–2011 2009–2010 2009–2011 2009–2010
*Italy included nine population based cancer registries: Registro Tumori Integrato (Catania
and Messina), Palermo, Ragusa, and Siracusa (Sicily-south of Italy); Modena, Parma,
Reggio Emilia, and Romagna (Emilia Romagna-centre of Italy); Friuli Venezia Giulia (Friuli
Venezia Giulia-north est of Italy).
and assessed by the observational study and QIs agreed by
consensus only. It was agreed that optimum management of
HNC patients requires active involvement of experts from a wide
variety of fields including at least: a head and neck surgeon, a
radiation oncologist, a pathologist, a radiologist and a medical
oncologist, high quality of surgery and radiotherapy, timely start
of treatment (12), optimal supportive care management, and the
ability to manage complex patients with multiple health and
social care needs.
The observation study was performed on 1,323, 928 and 6,185
cases of hypopharynx, larynx, oral cavity, and oropharynx SCC
in Ireland, Italy, and Netherlands, respectively. In Slovenia only
larynx SCC were included in study (N = 219) (Table 2).
Tables 3–5 summarize the results of the observational
assessment for the QIs included in the study by country.
Regarding staging at diagnosis (Table 3), in Netherlands and
Slovenia, almost all patients were staged (unknown stage <5%).
In Italy and Ireland, stage was unknown in about one out of six
and one out of four patients, respectively. Most of hypopharynx,
oropharynx, and oral cavity cancer patients were diagnosed with
an advanced disease stage across all countries.
Table 4 reports the results for the timeliness in starting
treatment and the adherence to CPG (Indicators 2, 3, 4, and
5). Many HNC patients started treatment with curative intent
(surgery or RT) >1 month after the diagnosis. In Italy, 60%
of HNC patients started the treatment within 1 month from
diagnosis, in all the other countries the proportion starting the
treatment on time decreased to 40%. Most of the HNC patients
started adjuvant treatment <8 weeks after surgery ranging from
52% in Italy to 79% in Netherlands. The only exception was
Ireland with 33% of HNC patients starting adjuvant within the
recommended number of days. Adherence to CPG was high
for HNC patients with localized disease stage (Indicator 4: 72–
79%) but low for HNC patients with advanced disease stage
(Indicator 5: 19–44%). Differences were observed in the use
of surgery and radiotherapy across head and neck sites and
countries. In Italy, surgery was the main treatment for all HNCs,
in the other countries RT was the main treatment for larynx
cancers and surgery for the other sites (data available from the
corresponding author).
Table 5 describes the quality of surgery and of the pathological
report after surgery (Indicators 6 and 11). CRs did not find
adequate information on type of RT thus results are not reported
for the indicator 9. The proportion of HNC patients with
complete tumor resection after a surgery with curative intent,
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TABLE 3 | Diagnostic management for head and neck cancers illustrated for larynx and other sites of the head and neck (i.e., hypopharynx, oral cavity and oropharynx),
by country.
Diagnostic management
Country Indicator 1. Percentage of patients with a defined stage at diagnosis
Larynx Other sites
N % L % A % M+ %Missing N % L % A % M+ %Missing
Ireland 449 40 35 3 22 874 17 55 4 24
Italy 398 50 30 4 16 530 24 49 8 19
Netherlands 2,102 58 37 1 4 4,083 38 55 2 4
Slovenia 219 54 41 1 4
Indicator 1: Number (N) of cases overall and percentage (%) of patients diagnosed with localized (L), advanced (A), and metastatic (M+) disease together with % of cases with information
on stage missing, by country.
ranged from 56% in Ireland to>70% in Netherland and Slovenia.
The resection margin was unknown in 27% of cases in Ireland
and in <15% of cases in the other countries. The pathological
report after surgery included all necessary information in a
minority of cases (from 1% in Slovenia to 24% in Italy). However,
in most cases (80–90%), at least site and laterality of the tumor,
histological type and grade were reported. The information less
often described weremaximum depth of invasion and the pattern
of invasion (data available from the corresponding author).
DISCUSSION
We proposed QIs of cancer care for HNCs based on
a multidisciplinary and expert-based consensus process at
European level. The proposed QIs cover two critical steps of
the patient journey (i.e., diagnosis and treatment) and are easy
to collect at the hospital as well as at the population level (i.e.,
fromCRs or administrative data sources). Previous QA for HNCs
focused on surgery (6, 7) and RT (4, 5). In addition, extensive
research have supported the important role of multidisciplinary
team (MDT) care for HNCs (2, 14–17).
The indicators proposed for surgery include: the presence
of a multidisciplinary tumor board advising on more than 90%
of HNCs, the capacity to perform all necessary imaging, the
existence of clinical pathways, collaboration with paramedical
services, institutional guidelines’ hygiene standards being
monitored by an institutional board, clinical trial data managers,
reports on surgical procedures as indicated by the American
Academy of Otolaryngology, Head and Neck Surgery, pathology
reports as indicated by the Royal College of Pathologists dataset
for histopathology reporting, established reporting system for
undesirable events (7).
General radiation oncology (RO)-QIs measure efficiency,
waiting time, accuracy of medical records, percentage of cases
discussed in a MDT setting, treatment planning based on CT,
frequency of verification of treatment portal, measures of physics
quality control adequacy, and patient satisfaction (18). For
HNC, the National Quality Measures Clearinghouse identified
two radiation oncology-related QI i.e., complete follow-up
documented for patients receiving RT for glottic cancer and
patients receiving post-operative head and neck RT 6 weeks
after surgery or longer (4). Guidelines for the delineation of the
primary tumor clinical target volumes are also available (19–21).
In addition, for HNCs, it is internationally agreed that RT-QA is
important, that a radiation oncologist should not practice HNC
without adequate training, and that a RT-QA program should
be available in RO departments treating HNC. To date, there
is no strict international consensus exists on the best model of
RT-QA, neither in relation to HNC nor otherwise. However,
the benefits of RT-QA and peer review suggest that this has
to be incorporated into routine clinical practice. Technology is
evolving at a rapid rate: machine learning, artificial intelligence,
deformable registration, and radiomics may bring additional
refinements to the peer review process. Peer review will form
an important component of adaptive treatment, but before this
is implemented we will need to consider how to best add this
additional burden to head and neck departments (5).
Our QIs include the quality of both, surgery and RT
and support the importance of MDT care, of timely start
of treatment and of the quality of the pathology reports. A
limitation of our QIs is that they do not address quality
in systemic therapy. Quality assurance in the medical arena
arrived most recently in comparison to other fields. At the
beginning of the 90s, the European organization for research
and treatment of cancer (EORTC) addressed issues related
to the practice of chemotherapy delivery and the quality of
data reporting. Furthermore, the EORTC quality assurance
committee proposed a minimal set of quality control procedures
to be implemented by all EORTC groups (10). However, QA
for medical oncology in HNCs was not developed further.
A major problem in HNCs medical oncology is the dose
intensity in multi therapy. HNC patients with locally advanced
disease stage treated with CRT experience moderate/severe
side-effects limiting their tolerance to receive the intended
cisplatin dose intensity (22). Chemotherapy modifications (dose
reductions/delays/omissions) are common (23–40%) (23, 24).
The consequence of cumulative cisplatin dose reduction is
uncertain although some reports suggest a possible detrimental
impact on survival (22, 23, 25). Discrepancies in treatment
adherence expressed as proportion of patients who received all
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planned cycles of chemotherapy could therefore be used as a QI
for systemic therapy in HNC. In this regard, there is an important
role for the clinician, not only to stimulate patients to adhere to
the treatment schedule, but also to provide optimal supportive
care in order to make it tolerable for the patient (22).
Previous studies looking at the quality of integrated care for
HNC patients proposed structure and process indicators (e.g.,
availability of MDT, of an integrated care pathway, of a case
manager, of electronic patient information system) (26, 27).
Other studies proposed an extensive list of outcome, process
and structure indicators that needed to be practically tested so
to limit the QIs number (1). Although interesting, these studies
report about one country-specific context. We tested the QIs
in an observational study performed in four different European
countries. The data collection, based on clinical dossiers and
administrative database, was undertaken with an acceptable
proportion of missing (<20–25%) in all countries and without
major problems in the data collection but for 1 RT indicator. The
expert panel agreed that the results of the observational study
gave a good description of the quality of care for HNCs in the
studies of all the countries, confirming the reliability and validity
of the QI proposed in measuring quality of care.
We found that quality of care of HNC does not reach optimal
standards in some of the countries analyzed. Many patients were
diagnosed an advanced disease stage, which is associated with
a worse prognosis (28). Another major problem was treatment
delay. This happened most likely when patients were treated
with RT, which could impact on their prognosis (29). Possible
explanations include possible delays in referral to RO and
concentration of radiotherapy facilities in a few centers with
limited resources. A recent survey on radiotherapy capacities
in Europe showed significant variability among countries and
a lack of RT infrastructures (30). The adherence to CPG for
treatment was good. However, we observed a very limited use
of multi therapy for advanced-stage patients. This is relevant
considering that they are associated with a higher survival
(31). We observed inadequate surgery and poor quality of
the pathological reports after surgery, which is a matter of
concern considering that pathological reports support treatment
decisions after surgery.
Our study adds evidence to previous national studies in which
compliance of HNCs care to hospital or national CPG was
considered a quality care marker. A Dutch study reported a
compliance rate of 91% (32), one study from the USA 86% (33),
going down to 57% in patients with persistent or recurrent HNCs
who were referred to an expert centre (34).
Limitations of our study include the retrospective design
and the potential errors in coding associated with the kind of
sources of clinical data and their inherent variability in quality
of reporting, although every effort was made to standardize
data collection and reduce missing data. Strengths are the
centralization of data quality checks and analyses along with
the population-based nature of this effort, which is essential to
generate real-world data.
Our results showed suboptimal standards of quality of care in
some of the countries analyzed and call for solutions to increase
quality care for HNC patients to ensure high quality of care
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TABLE 5 | Quality of surgery and of the pathological report after surgery.
Quality of surgery and of the pathological report after surgery
Country Indicator 6% of complete tumor
resection
Indicator 11% of pathology reports
with all core data
N treated with surgery
with curative intent
% of R0 M% N surgically
treated
% of post-surgery
pathological report with
all core data
M%
Ireland 602 56 27 NA NA
Italy 516 62 13 474 24 2
Netherlands 2,728 74 13 128** 16** 0
Slovenia 88 75 9 87 1 29
Indicator 6: Number (N) of head and neck patients treated with surgery with curative intent*, percentage (%) of head and neck patients treated with surgery with negative resection margins
(R0) and percentage (%) of missing (M) information for this indicator. Indicator 11: Number (N) of head and neck patients treated with surgery (excluding cryotherapy photodynamic
therapy or electrocautery procedure, cryosurgery or laser therapy or thermo-ablation), percentage (%) of pathological report after surgery with all the information available and percentage
(%) of missing (M) information for this indicator. *Surgery with curative intent: surgery alone or surgery + adjuvant treatment.
NA, not available. **Evaluated on a sample of 200 randomly selected case.
across EU countries. One way of increasing quality of care for
HNC patients is to refer them to specialized centers or networks
involving specialized centers. Thus, the available evidence show
that in the high volume context quality of care is ensured in the
entire patient journey:
1) The specialized MDT, which takes considerable time, effort
and financial resources works better (35); furthermore the
presence of aMDT in high-volume and referral cancer centers
is associated with better therapeutic decision (35);
2) The minimal level of quality of surgery is most likely to
be reached considering the structural and process criteria
identified by the QA programme and the number of major
head and neck procedures that should be performed by a
leading surgeon per year (7),
3) Experienced clinicians are available to deliver complex HNC
RT treatment most accurately and to peer review RT complex
plans ensuring RT-QA program (5).
Furthermore, high volume seems to be associated also with better
outcomes for HNCs (36–38).
Centralization for many rare cancers including HNCs is
still limited in many countries in Europe (39). Gatta et al.
reported that for HNCs, 75% of patients were centralized
in two top hospitals in Slovenia (2 million population, 266
treatments per hospital per year), and 12 top hospitals in
the Netherlands (17 million population, 201 treatments per
hospital per year). The level of centralization was lower in
the other countries included in the study, resulting in a
caseload of 145 treatments/year on overage in each of the
10 Bulgarian top hospitals, 106 treatments/year on average
in each of the 29 top Belgian hospitals, 83 treatments/year
on average in each of the top six hospitals in Finland, 77
treatments/year on average in the two top hospitals in Navarra,
and 63 treatments/year on average in the top seven hospitals in
Ireland (39).
It follows that the centralization of care, although hardly
feasible for all HNC patients, should be an objective to be
pursued. We strongly believe that this objective can only be
achieved by progressively making it a national health care
policy priority.
The quality ensured by the case volume could be explained by
several factors: organization, facilities, processes of care, quality
assurance programs, professional expertise, adherence to clinical
protocols, technology. In this context, it will be important to
detect which of these factors influences final outcomes among
HNC patients. We are currently performing additional analyses
to assess the relationship between hospital volume and the QIs
proposed. We are also trying to assess whether the proposed QIs
can explain the observed higher survival observed in high volume
centers. In this paper, we present the QI and the process behind
their definition. Furthermore, we provide data on quality of care
for HNC patients across four countries. This study may be a
starting point showing the variability in clinical practice as well
as the need to make every effort to increase quality of care for
HNC patients in all EU countries.
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